HomeCompareVMCAU vs ABBV

VMCAU vs ABBV: Dividend Comparison 2026

VMCAU yields 17.59% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $39.4K in total portfolio value· pulled ahead in Year 8
10 years
VMCAU
VMCAU
● Live price
17.59%
Share price
$11.37
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$62.9K
Annual income
$5,164.18
Full VMCAU calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — VMCAU vs ABBV

📍 ABBV pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVMCAUABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VMCAU + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VMCAU pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VMCAU
Annual income on $10K today (after 15% tax)
$1,495.16/yr
After 10yr DRIP, annual income (after tax)
$4,389.55/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $16,666.45/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VMCAU + ABBV for your $10,000?

VMCAU: 50%ABBV: 50%
100% ABBV50/50100% VMCAU
Portfolio after 10yr
$82.6K
Annual income
$14,967.97/yr
Blended yield
18.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

VMCAU
No analyst data
Altman Z
2.9
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VMCAU buys
0
ABBV buys
0
No recent congressional trades found for VMCAU or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVMCAUABBV
Forward yield17.59%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$62.9K$102.3K
Annual income after 10y$5,164.18$24,771.77
Total dividends collected$33.4K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VMCAU vs ABBV ($10,000, DRIP)

YearVMCAU PortfolioVMCAU Income/yrABBV PortfolioABBV Income/yrGap
1$12,459$1,759.01$11,550$430.00+$909.00VMCAU
2$15,379$2,048.19$13,472$627.96+$1.9KVMCAU
3$18,819$2,362.87$15,906$926.08+$2.9KVMCAU
4$22,838$2,702.15$19,071$1,382.55+$3.8KVMCAU
5$27,502$3,064.76$23,302$2,095.81+$4.2KVMCAU
6$32,876$3,449.13$29,150$3,237.93+$3.7KVMCAU
7$39,031$3,853.40$37,536$5,121.41+$1.5KVMCAU
8← crossover$46,038$4,275.51$50,079$8,338.38$4.0KABBV
9$53,974$4,713.23$69,753$14,065.80$15.8KABBV
10$62,917$5,164.18$102,337$24,771.77$39.4KABBV

VMCAU vs ABBV: Complete Analysis 2026

VMCAUStock

Valuence Merger Corp. I focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to identify, acquire, and operate a business in Asia with a focus on opportunities aligned with breakthrough technology in life sciences and sustainability technology themes. The company was incorporated in 2021 and is based in Orinda, California.

Full VMCAU Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this VMCAU vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VMCAU vs SCHDVMCAU vs JEPIVMCAU vs OVMCAU vs KOVMCAU vs MAINVMCAU vs JNJVMCAU vs MRKVMCAU vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.